

Declaration of Nicholas Hill in Support of
Petition for *Inter Partes* Review
of U.S. Patent No. 10,716,793 B2

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

LIQUIDIA TECHNOLOGIES, INC.,
Petitioner

v.

UNITED THERAPEUTICS CORPORATION,
Patent Owner

U.S. Patent No. 10,716,793 B2

DECLARATION OF NICHOLAS HILL, M.D.

TABLE OF CONTENTS

	Page
I. INTRODUCTION	1
II. QUALIFICATIONS	2
A. Qualifications and Experience	2
B. Materials Considered.....	4
III. PERSON OF ORDINARY SKILL IN THE ART	7
IV. STATEMENT OF LEGAL PRINCIPLES.....	8
V. RELEVANT TECHNICAL BACKGROUND	11
A. Overview of Pulmonary Hypertension.....	11
B. Well Known Advantages of Inhalation Therapy and Inhalers.....	12
C. Considerations for Inhalation Therapy.....	13
D. Treprostinil	15
VI. THE '793 PATENT	17
VII. APPLICATION OF THE PRIOR ART TO THE CLAIMS.....	19
A. Brief Summary of Prior Art	20
1. '212 Patent [Ex. 1006]	20
2. Voswinckel JESC [Ex. 1007]	23
3. Voswinckel JAHA [Ex. 1008]	26
4. Ghofrani [Ex. 1010]	26
5. Voswinckel 2006 [Ex. 1009]	27
B. Ground 1: Claims 1–8 are Obvious over '212 Patent in View of Voswinckel JAHA and Voswinckel JESC.....	28
1. Motivation to Combine the '212 Patent with Voswinckel JAHA and Voswinckel JESC with a Reasonable Expectation of Success	28
2. Independent Claim 1	32

(a)	“A method of treating pulmonary hypertension comprising administering by inhalation to a human suffering from pulmonary hypertension a therapeutically effective single event dose of a formulation comprising treprostinil or a pharmaceutically acceptable salt thereof” (Claim 1[a]).....	33
(b)	“with an inhalation device,” (Claim 1[b])	35
(c)	“wherein the therapeutically effective single event dose comprises from 15 micrograms to 90 micrograms of treprostinil or a pharmaceutically acceptable salt thereof” (Claim 1[c]).....	36
(d)	“delivered in 1 to 3 breaths.” (Claim 1[d]).....	39
3.	Dependent Claim 2	41
4.	Dependent Claim 3	42
5.	Dependent Claim 4	43
6.	Dependent Claim 5	44
7.	Dependent Claims 6, 7, and 8	44
C.	Ground 2: Claims 1–8 are Obvious over ’212 Patent in View of Voswinckel JESC	46
1.	Motivation to Combine the ’212 Patent with Voswinckel JESC With a Reasonable Expectation of Success	46
2.	Independent Claim 1	47
(a)	“A method of treating pulmonary hypertension comprising administering by inhalation to a human suffering from pulmonary hypertension a therapeutically effective single event dose of a formulation comprising treprostinil or a pharmaceutically acceptable salt thereof with an inhalation device, wherein the therapeutically effective single event dose comprises from 15 micrograms to 90 micrograms of treprostinil or a pharmaceutically acceptable salt thereof” (Claim 1[a][b][c])	47
(b)	“delivered in 1 to 3 breaths.” (Claim 1[d]).....	47

3.	Dependent Claims 2-8.....	49
D.	Ground 3: Claim 1 is anticipated by Ghofrani	50
1.	Independent Claim 1	50
(a)	“A method of treating pulmonary hypertension comprising administering by inhalation to a human suffering from pulmonary hypertension a therapeutically effective single event dose of a formulation comprising treprostinil or a pharmaceutically acceptable salt thereof” (Claim 1[a]).....	50
(b)	“with an inhalation device,” (Claim 1[b])	51
(c)	“wherein the therapeutically effective single event dose comprises from 15 micrograms to 90 micrograms of treprostinil or a pharmaceutically acceptable salt thereof” (Claim 1[c]).....	52
(d)	“delivered in 1 to 3 breaths.” (Claim 1[d]).....	52
E.	Ground 4: Claims 1, 3, and 8 are Obvious over Voswinckel JAHA and Ghofrani	53
1.	Motivation to Combine Voswinckel JAHA and Ghofrani With a Reasonable Expectation of Success	53
2.	Independent Claim 1	55
(a)	“A method of treating pulmonary hypertension comprising administering by inhalation to a human suffering from pulmonary hypertension a therapeutically effective single event dose of a formulation comprising treprostinil or a pharmaceutically acceptable salt thereof” (Claim 1[a]).....	55
(b)	“with an inhalation device,” (Claim 1[b])	56
(c)	“wherein the therapeutically effective single event dose comprises from 15 micrograms to 90 micrograms of treprostinil or a pharmaceutically acceptable salt thereof” (Claim 1[c]).....	57
(d)	“delivered in 1 to 3 breaths.” (Claim 1[d]).....	58
3.	Dependent Claim 3	58

4.	Dependent Claim 8	58
F.	Ground 5: Claims 1 and 3 are Anticipated by Voswinckel 2006	59
1.	Independent Claim 1	59
	(b) “A method of treating pulmonary hypertension comprising administering by inhalation to a human suffering from pulmonary hypertension a therapeutically effective single event dose of a formulation comprising treprostinil or a pharmaceutically acceptable salt thereof” (Claim 1[a]).....	59
	(c) “with an inhalation device,” (Claim 1[b])	60
	(d) “wherein the therapeutically effective single event dose comprises from 15 micrograms to 90 micrograms of treprostinil or a pharmaceutically acceptable salt thereof” (Claim 1[c]).....	60
	(e) “delivered in 1 to 3 breaths.” (Claim 1[d]).....	60
2.	Dependent Claim 3	61
G.	Ground 6: Claims 2 and 4–8 are Obvious over Voswinckel 2006 and the ’212 Patent	61
1.	Motivation to Combine Voswinckel 2006 and the ’212 Patent with a Reasonable Expectation of Success	61
2.	Dependent Claim 2	63
3.	Dependent Claim 4	63
4.	Dependent Claim 5	64
5.	Dependent Claim 6, 7, and 8.....	64
VIII.	NO SECONDARY CONSIDERATIONS OF NON-OBVIOUSNESS	66
IX.	CONCLUSION.....	67

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.